pretickt

Amgen Inc. (AMGN)

Healthcare · end-of-day data as of Oct 16, 2026

Amgen Inc.
AMGN · $234B
$432.49+15.7%last 60 sessions · close Oct 16, 2026
$283.30$444.1252 weeks
Hold · 34 analystsPT $400.03 -7.5%
  • P/E vs own+17.1%
  • P/E vs sector-4.5%
  • Target upside-7.5%
  • Off 52w high-2.6%
  • Insiders-$2.48M
  • FCF yield+4.4%
  • Earnings in18d
  • Trendbullish
  • Sector▲ +16.0%
  • RSI63
  • MA20×50↑ in ~1d
  • Volume0.9x
  • Support-10.5%
  • Resistance+2.7%

The average 12-month analyst price target for AMGN is $400.03, 7.5% below the last close of $432.49 on Oct 16, 2026; targets range from $239.11 to $500.50. Rating consensus: Hold.

Snapshot

  • P/E26.9x
  • P/E vs sector-4.5%
  • P/E vs own+17.1%
  • Target upside-7.5%
  • ConsensusHold
  • Market cap$234B
  • FCF yield+4.4%
  • Insiders-$2.48M
  • Earnings in18d
  • News

Why it moved

Amgen Inc. (AMGN) fell 0.4% on Oct 16, 2026.

The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.

Market (SPY)-1.1%
Healthcare sector+0.4%
AMGN specific+0.4%

1 story on the day (30-day average 1.5).

Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.

Price and events

⇔⇕$294$340$387$434Oct 25Jan 26Apr 26Jul 26Oct 26EDAEADEDEDAAE

Last close $432.49 · +50.3% over 1y · E earnings · D dividend · S split · A analyst rating change

Technicals

  • Trendbullish
  • Sector▲ +16.0%
  • MAs20▲ 50▲ 100▲ 200▲
  • Above MAs4 of 4 above
  • MA20×50↑ in ~1d
  • RSI63
  • Support-10.5%
  • Resistance+2.7%
  • Off 52w high-2.6%
  • Off ATH-2.6%
  • 52w range$432.49
  • Bollingerupper half
  • MACD2.78
  • ATR+2.5%
  • Volume0.9x

Analyst price targets

Low$239.11
Average$400.03
Median$405.85
High$500.50
Upside-7.5%

21 firms with a target in the last 12 months · last close $432.49 · as of Oct 16, 2026

⇔⇕$167$254$342$429$516Oct 25Mar 26Aug 26Jan 27Jun 27-29%-10%-19%+0%-58%-23%-11%-31%+0%-45%
— actual price● bullish target● bearish targethover a dot to see the analysts behind it · wheel or drag to move through time · drag the price axis on the right to stretch it · double-click resets

Strong buy 4 · Buy 8 · Hold 17 · Sell 3 · Strong sell 2

Revenue and free cash flow

Q2 FY2026: Revenue +9.7% year over year, free cash flow 34.7% of revenue, operating margin 35.0%.

RevenueFree cash flow
Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026
Q2 FY2026Jun 30, 2026$10.05B4.37$3.49B72.0%35.0%23.6%
Q1 FY2026Mar 31, 2026$8.62B3.34$1.48B68.2%30.9%21.1%
Q4 FY2025Dec 31, 2025$9.9B2.45$961M81.9%39.8%13.5%
Q3 FY2025Sep 30, 2025$9.56B5.93$4.25B67.8%26.4%33.7%
Q2 FY2025Jun 30, 2025$9.17B2.65$1.91B67.2%28.8%15.6%
Q1 FY2025Mar 31, 2025$8.15B3.20$980M63.6%14.5%21.2%
Q4 FY2024Dec 31, 2024$9.09B1.16$4.4B65.7%25.4%6.9%
Q3 FY2024Sep 30, 2024$8.5B5.22$3.31B61.1%24.1%33.3%

Peers

20D
1LLYEli Lilly and Company$1,257.03+0.4%-1.8%+4.5%42.2$1.18T
2JNJJohnson & Johnson$255.56+0.9%-8.2%+8.8%38.7$616B
3ABBVAbbVie Inc.$285.42+0.7%0.0%-1.4%80.4$504B
4MRKMerck & Co., Inc.$145.95+0.5%-6.2%+7.7%116.8$360B
5AMGNAmgen Inc.$432.49-0.4%-2.6%-7.5%26.9$234B
6GILDGilead Sciences, Inc.$156.19-0.7%-0.7%+1.9%—$194B
7PFEPfizer Inc.$29.58+0.5%0.0%-7.1%39.1$169B
8BMYBristol-Myers Squibb Company$59.75-1.4%-11.3%+9.4%13.2$122B

Data as of Oct 16, 2026 close.

Latest news

Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.